Zevra Therapeutics (ZVRA) to Release Quarterly Earnings on Thursday

Zevra Therapeutics (NASDAQ:ZVRA) will likely be announcing its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.39) per share and revenue of $8.93 million for the quarter. Investors interested in listening to the company’s conference call can do so using this link.

Zevra Therapeutics (NASDAQ:ZVRA) last posted its quarterly earnings data on Tuesday, March 11th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.28). The business had revenue of $12.00 million during the quarter, compared to the consensus estimate of $8.93 million. Zevra Therapeutics had a negative net margin of 342.63% and a negative return on equity of 159.54%. On average, analysts expect Zevra Therapeutics to post $-2 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Zevra Therapeutics Stock Performance

NASDAQ ZVRA opened at $7.95 on Thursday. The company has a quick ratio of 2.88, a current ratio of 2.88 and a debt-to-equity ratio of 0.84. The company has a market capitalization of $430.22 million, a P/E ratio of -4.04 and a beta of 1.98. Zevra Therapeutics has a 12-month low of $4.20 and a 12-month high of $9.76. The firm has a 50-day moving average price of $7.91 and a two-hundred day moving average price of $8.17.

Insider Buying and Selling

In related news, EVP Joshua Schafer sold 10,500 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $7.86, for a total transaction of $82,530.00. Following the completion of the transaction, the executive vice president now directly owns 29,486 shares in the company, valued at $231,759.96. This represents a 26.26 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Neil F. Mcfarlane sold 61,273 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $7.86, for a total transaction of $481,605.78. Following the transaction, the chief executive officer now owns 222,060 shares of the company’s stock, valued at approximately $1,745,391.60. This represents a 21.63 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 85,773 shares of company stock worth $674,176 in the last three months. 2.40% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ZVRA. Guggenheim boosted their target price on shares of Zevra Therapeutics from $20.00 to $22.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. HC Wainwright restated a “buy” rating and issued a $20.00 target price on shares of Zevra Therapeutics in a research report on Thursday, March 13th. Citigroup restated an “outperform” rating on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Canaccord Genuity Group boosted their target price on shares of Zevra Therapeutics from $23.00 to $25.00 and gave the company a “buy” rating in a research report on Thursday, March 13th. Finally, JMP Securities set a $18.00 target price on shares of Zevra Therapeutics in a research report on Wednesday, March 12th. Eight research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus price target of $22.29.

About Zevra Therapeutics

Zevra Therapeutics, Inc discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy.